PAM
CTKB icon

Panagora Asset Management’s Cytek Biosciences CTKB Stock Holding History

Panagora Asset Management’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-51,593
Closed -$225K – 1206
2026
Q1 		$225K Hold
51,593
– – ﹤0.01% 1064
2025
Q4 		$261K Sell
51,593
-11,005
-18% -$51.1K ﹤0.01% 1043
2025
Q3 		$217K Sell
62,598
-225,664
-78% -$847K ﹤0.01% 1072
2025
Q2 		$980K Sell
288,262
-120,664
-30% -$402K ﹤0.01% 631
2025
Q1 		$1.64M Buy
408,926
+281,928
+222% +$1.46M 0.01% 559
2024
Q4 		$824K Buy
+126,998
New +$757K ﹤0.01% 701

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Panagora Asset Management's CTKB Position: Q2 2026 in Review

Panagora Asset Management sold out of Cytek Biosciences (CTKB) in Q2 2026, closing a stake of 51,593 shares — an estimated $225K sold.

Panagora Asset Management first reported a position in CTKB in Q4 2024 and held it in 6 quarters. The position peaked at $1.64M in Q1 2025. 155 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • Panagora Asset Management reported no remaining Cytek Biosciences position as of Q2 2026 after selling out during the quarter.
  • Panagora Asset Management sold 51,593 Cytek Biosciences shares in Q2 2026, an estimated $225K.
  • Panagora Asset Management first reported a position in Cytek Biosciences in Q4 2024 and held it in 6 quarters.
  • Panagora Asset Management's Cytek Biosciences position peaked at $1.64M in Q1 2025.
  • 155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Panagora Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.